ESA Hyporesponsiveness in Hemodialysis Patients

September 28, 2026 updated by: Hamid Ibrahim Hamid, Assiut University

Predictors of Development and Persistence of Erythropoietin-Stimulating Agents Hyporesponsiveness in Hemodialysis Patients

This prospective cohort study aims to evaluate the development, persistence, and recovery of erythropoiesis-stimulating agent (ESA) hyporesponsiveness among patients receiving maintenance hemodialysis.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Anemia is a common complication in patients receiving maintenance hemodialysis. Response to erythropoiesis-stimulating agents varies, and some patients develop hyporesponsiveness.

This observational study will include adult patients on maintenance hemodialysis who are receiving ESA therapy. The erythropoietin resistance index (ERI) will be calculated at baseline and during 12 months of follow-up to identify development, persistence, and recovery of ESA hyporesponsiveness.

Study Type

Observational

Enrollment (Estimated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adult patients with end-stage renal disease receiving maintenance hemodialysis at the Hemodialysis Center, Assiut University Hospital.

Description

Inclusion Criteria:

  • Age ≥18 years.
  • ESRD/CKD G5D receiving maintenance hemodialysis.
  • Hemodialysis ≥3 months before enrollment.
  • Receiving ESA therapy for anemia.
  • Expected to remain on hemodialysis during the study period.
  • Baseline Hb and ESA dose available.

Exclusion Criteria:

  • Active malignancy.
  • Hematological malignancy.
  • Known hemoglobinopathy causing anemia.
  • Recent blood transfusion, e.g. within 3 months before enrollment.
  • Recent major surgery.
  • Active major bleeding.
  • Pregnancy.
  • Recent kidney transplantation.
  • Known pure red-cell aplasia.
  • Incomplete clinical or laboratory follow-up

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Single cohort: Maintenance Hemodialysis Patients

Adult patients receiving maintenance hemodialysis and ESA therapy who will be followed for 12 months to assess development, persistence, and recovery of ESA hyporesponsiveness.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of new-onset ESA hyporesponsiveness
Time Frame: 12 months

Proportion of patients who develop new-onset ESA hyporesponsiveness, defined as erythropoietin resistance index (ERI) > 15.4 during the 12-month follow-up.

12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of patients with persistent ESA hyporesponsiveness
Time Frame: 12 months

Proportion of patients with ESA hyporesponsiveness (ERI > 15.4) persisting for more than 4 months.

12 months
Proportion of patients who recover from ESA hyporesponsiveness
Time Frame: 12 months

Proportion of patients who recover from ESA hyporesponsiveness (ERI ≤ 15.4) during follow-up.

12 months
Mean erythropoietin resistance index
Time Frame: Baseline and at 12 months

Mean erythropoietin resistance index (ERI) calculated as weekly ESA dose (IU/week) / [body weight (kg) × hemoglobin (g/dL)].

Baseline and at 12 months
Mean serum ferritin
Time Frame: Baseline and at 12 months

Mean serum ferritin level in ng/mL.

Baseline and at 12 months
Mean serum albumin
Time Frame: Baseline and at 12 months

Mean serum albumin level in g/dL.

Baseline and at 12 months
Mean C-reactive protein
Time Frame: Baseline and at 12 months

Mean C-reactive protein (CRP) level in mg/L.

Baseline and at 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Chair: Marwa k Abdo, prof, Internal Medicine Department, Assiut University Hospitals

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 2, 2026

Primary Completion (Estimated)

October 1, 2027

Study Completion (Estimated)

March 1, 2028

Study Registration Dates

First Submitted

September 28, 2026

First Submitted That Met QC Criteria

September 28, 2026

First Posted (Actual)

October 2, 2026

Study Record Updates

Last Update Posted (Actual)

October 2, 2026

Last Update Submitted That Met QC Criteria

September 28, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • ESA-Hyporesponse-Assiut-2026

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.